Prosensa Holding BV (RNA)

[oldberkeley]

Here's a quote from mid-January, they must be referring to this:

Prosensa is still considering a regulatory filing of drisapersen, given the mid-stage study showed promise in treating patients in the early stage of disease, Chief Executive Officer Hans Schikan said in a telephone interview. Longer treatment may also benefit patients, he said.

"When you start the treatment and how long you treat are the key questions," Schikan said. Full analysis of the trials has not yet been completed, he said.